REMARKS

Applicants respectfully request acceptance of the enclosed paper copy and computer readable form of the Sequence Listing.

It is respectfully asserted that the sequence disclosure contained in the application now fully complies with the requirements set forth in 37 C.F.R. § 1.821 to § 1.825. Accordingly, reconsideration of Applicants failure to comply with the sequence listing rules is respectfully requested.

It is respectfully submitted that the Sequence Listing conforms to the requirements of 37 C.F.R. §1.823(b). The Statements required by 37 C.F.R §1.821(f) and (g) are set forth below.

Pursuant to 37 C.F.R. §1.821 (g), the undersigned hereby states that this submission, filed in accordance with 37 C.F.R. §1.821 (g), does not contain new matter.

Pursuant to 37 C.F.R. §1.821 (f), the undersigned hereby states that the content of the paper and computer readable copies of the Sequence Listing submitted in accordance with 37 C.F.R. §1.821 (c) and (e), respectively, are the same.

In view of the amendments, remarks and enclosures herewith, the application complies with the requirements of the 37 C.F.R. §1.821-1.825 relating to nucleotide and/or amino acid sequences.

CONCLUSION

In view of the enclosures herein, and also in view of the Supplemental Preliminary Amendment being concurrently filed, the present application is in compliance with the requirements set forth in 37 C.F.R. § 1.821 to § 1.825. Early and favorable consideration of the application on the merits, and Allowance of the application, are earnestly solicited.

Respectfully submitted,

FROMMER LAWRENCE & HAUG LLP Attorney for Applicants

//~

Ronald R. Santucci Reg. No. 28,988 (212) 588-0800